Propel Bio Management
Latest statistics and disclosures from Propel Bio Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are PAGP, ACHV, PHAT, VRDN, MIST, and represent 61.96% of Propel Bio Management's stock portfolio.
- Added to shares of these 10 stocks: KYTX (+$6.3M), VRDN (+$6.0M), IVA, OCS, PHAT, SABS, CMPS, RGNX, NKTR, LENZ.
- Started 8 new stock positions in KYTX, SABS, LENZ, KLRS, OCS, RGNX, IVA, AARD.
- Reduced shares in these 8 stocks: AKRO (-$11M), Applied Therapeutics (-$6.8M), TCRX, JSPR, MIST, ZVRA, ABEO, CLDX.
- Sold out of its positions in AKRO, Applied Therapeutics, JSPR, TCRX.
- Propel Bio Management was a net buyer of stock by $5.4M.
- Propel Bio Management has $117M in assets under management (AUM), dropping by 17.25%.
- Central Index Key (CIK): 0001969764
Tip: Access up to 7 years of quarterly data
Positions held by Propel Bio Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Propel Bio Management
Propel Bio Management holds 20 positions in its portfolio as reported in the December 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Plains Gp Hldgs Ltd Partnr Int A (PAGP) | 20.8 | $24M | 1.3M | 19.14 |
|
|
| Achieve Life Sciences (ACHV) | 16.1 | $19M | 3.8M | 4.97 |
|
|
| Phathom Pharmaceuticals (PHAT) | 10.5 | $12M | +33% | 741k | 16.59 |
|
| Miragen Therapeutics (VRDN) | 7.5 | $8.8M | +213% | 283k | 31.12 |
|
| Milestone Pharmaceuticals (MIST) | 7.1 | $8.3M | -19% | 4.1M | 2.02 |
|
| Kyverna Therapeutics (KYTX) | 5.4 | $6.3M | NEW | 667k | 9.40 |
|
| Compass Pathways Sponsored Ads (CMPS) | 5.1 | $5.9M | +68% | 862k | 6.90 |
|
| Inventiva Sa - Ads (IVA) | 4.0 | $4.7M | NEW | 1.0M | 4.65 |
|
| Delcath Systems Com New (DCTH) | 3.8 | $4.4M | 439k | 10.10 |
|
|
| Abeona Therapeutics Com New (ABEO) | 3.7 | $4.4M | -14% | 831k | 5.27 |
|
| Celldex Therapeutics Com New (CLDX) | 3.6 | $4.2M | 154k | 27.16 |
|
|
| Nektar Therapeutics Com New (NKTR) | 3.0 | $3.5M | +69% | 83k | 42.28 |
|
| Oculis Holding Ordinary Shares (OCS) | 2.9 | $3.5M | NEW | 173k | 19.97 |
|
| Sab Biotherapeutics Com New (SABS) | 2.1 | $2.4M | NEW | 653k | 3.74 |
|
| Regenxbio Inc equity us cm (RGNX) | 1.4 | $1.7M | NEW | 117k | 14.40 |
|
| Athira Pharma | 1.0 | $1.1M | 149k | 7.57 |
|
|
| Lenz Therapeutics (LENZ) | 0.8 | $945k | NEW | 59k | 16.00 |
|
| Aardvark Therapeutics (AARD) | 0.5 | $609k | NEW | 46k | 13.12 |
|
| Zevra Therapeutics Com New (ZVRA) | 0.5 | $571k | -72% | 64k | 8.96 |
|
| Kalaris Therapeutics (KLRS) | 0.3 | $355k | NEW | 42k | 8.44 |
|
Past Filings by Propel Bio Management
SEC 13F filings are viewable for Propel Bio Management going back to 2023
- Propel Bio Management 2025 Q4 filed Feb. 11, 2026
- Propel Bio Management 2025 Q3 filed Nov. 12, 2025
- Propel Bio Management 2025 Q2 filed Aug. 13, 2025
- Propel Bio Management 2025 Q1 filed May 15, 2025
- Propel Bio Management 2024 Q4 filed Feb. 14, 2025
- Propel Bio Management 2024 Q3 filed Nov. 13, 2024
- Propel Bio Management 2024 Q2 filed Aug. 12, 2024
- Propel Bio Management 2024 Q1 filed May 13, 2024
- Propel Bio Management 2023 Q4 filed Feb. 14, 2024